We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
- Authors
Chlebowski, Rowan T; Aragaki, Aaron K; Pan, Kathy
- Abstract
Both estrogen plus progestin and estrogen alone are described as increasing breast cancer incidence and mortality in women without breast cancer history, citing 2 large observational studies published in 2019. Clinicians, and especially breast cancer survivors, should be aware of the limitations of the conclusions of Cold and colleagues ([1]) regarding MHT safety for use after breast cancer, especially in consideration of the mortality risk associated with breast cancer recurrence. After 20 years of follow-up and 1565 incident breast cancers, estrogen plus progestin increased breast cancer incidence, whereas estrogen alone decreased breast cancer incidence and breast cancer mortality ([2]).
- Subjects
CANCER relapse; BREAST cancer; HORMONE therapy; COHORT analysis; SCIENTIFIC observation; CANCER hormone therapy
- Publication
JNCI: Journal of the National Cancer Institute, 2023, Vol 115, Issue 2, p222
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djac213